Reference Group Trial for The ONE Study

End-stage Renal Failure Clinical Trial

Official title:
Reference Group Trial for The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation

Status Completed

Clinical Trial Summary

To investigate the progression of the immunological response in living-donor kidney transplant recipients treated with a standard immunosuppressive regimen. Clinical, immunological, and health-economic data collected during this Reference Group Trial will be used to corroborate historical renal transplantation statistics and generate reference ranges for future clinical studies that will test immunoregulatory cell therapy as an adjunct immunosuppressive treatment in renal transplantation.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01656135
Study type	Interventional
Source	University of Regensburg
Contact
Status	Completed
Phase	Phase 4
Start date	December 2012
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01449266` - Safety and Dialysability of Dotarem® in Dialysed Patients	Phase 1
Completed	`NCT01126905` - Mean Reticulated Haemoglobin (Hb) Content (RetHe) Analysis of Renal Patients
Completed	`NCT00807144` - Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation	Phase 4
Active, not recruiting	`NCT00238043` - Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia	Phase 3
Completed	`NCT02129881` - The ONE Study UK Treg Trial	Phase 1/Phase 2
Completed	`NCT01687699` - Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients	Phase 4